)
Visual
test
Definium Therapeutics Inc
Definium Therapeutics Inc (DFTX) investor relations material
Definium Therapeutics Inc 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary14 Jan, 2026
Strategic vision and rebranding
Recently rebranded to signal a new era with multiple pivotal clinical readouts ahead.
Focused on establishing leadership in psychiatric therapeutics, especially for anxiety and depression.
Emphasizes the need for innovation in psychiatry, given decades of limited progress.
Aims to address the large, underserved population affected by anxiety and depression, estimated at 50 million U.S. adults.
Seeks to drive meaningful, long-lasting change in patient outcomes.
Clinical development and data highlights
Lead candidate DT120 (LSD/lysergide) is in multiple phase III studies for generalized anxiety disorder (GAD) and major depressive disorder (MDD).
Phase II data showed a rapid, durable effect with a 0.81 effect size and 48% remission rate after a single dose in GAD.
Phase II also demonstrated a drug effect more than double that of approved therapies, with a 22-point reduction on the Hamilton Anxiety Scale.
Three pivotal phase III readouts are expected in 2024: two in GAD and one in MDD.
Phase III studies are designed to address placebo effects and maximize robust, reliable outcomes.
Market opportunity and commercial strategy
Psychiatry market is primed for innovation, with high unmet need and strong interest from providers and payers.
DT120's single-dose, long-lasting effect differentiates it from existing treatments requiring frequent administration.
Pricing is expected to benchmark against Spravato, with flexibility to adjust post-approval.
Commercial launch preparations include targeting high-volume GAD prescribers and building a comprehensive go-to-market strategy.
Over 50% of high-decile HCPs intend to prescribe/administer DT120, with rapid early adoption anticipated.
Phase III placebo effect mitigation strategy
DT120 care model scalability vs. esketamine
DT120 pricing strategy and payer expectations
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 7 Feb517271
Strong revenue and profit growth, interim dividend, and major investments approved. - 7 Feb514167
Quarterly and nine-month results reflect solid revenue, profit, and compliance with new labour codes. - 7 FebMGL
Strong revenue growth offset by lower margins and profit; interim dividend declared. - 7 FebPGIL
Strong revenue and margin growth, with India set for further expansion and upgraded ratings. - 7 Feb504614
Strong revenue and profit growth in Q3 FY26, led by power and steel segments. - 7 FebCHEMPLASTS
Net losses widened and revenue fell year-over-year amid regulatory and market headwinds. - 7 FebSBIN
Q3 FY26 net profit reached ₹21,028.15 crore, driven by robust income and strategic divestments. - 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus. - 6 FebWEC
Targets 7–8% EPS growth, $37.5B capex, and coal exit by 2032 amid surging data center demand.
Next Definium Therapeutics Inc earnings date
Q4 20255 Mar, 2026
Definium Therapeutics Inc
Next Definium Therapeutics Inc earnings date
Q4 20255 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Mind Medicine (MindMed) Inc is a biopharmaceutical company focused on the development of psychedelic-inspired medicines and therapies for mental health and addiction conditions. The company engages in clinical research and product development targeting various psychiatric and neurological disorders. MindMed operates within the healthcare and biotechnology sectors. The company is headquartered in New York, New York, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage